Captor Therapeutics S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-11-07
Share capital
636,233.10 PLN
Activity description

Captor Therapeutics is a biotech company that utilizes Targeted Protein Degradation (TPD) technology to discover and develop therapies for diseases with unmet medical needs, such as cancer and autoimmune disorders. The company operates from Basel, Switzerland, and Wrocław, Poland, and employs advanced techniques like CRISPR/Cas9 for genome editing and its Optigrade™ platform for drug candidate discovery. Their integrated expertise in protein engineering, structural biology, and molecular modeling enables them to optimize lead compounds effectively.

Registered address
ul. Duńska 11, 54-427 Wrocław, Poland
Phone
Social media
Electronic delivery address
AE:PL-88161-66597-WVWGS-21

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 26 days early. All were audited by a statutory auditor.

  • 202525/06/2026
  • 202402/07/2025
  • 202302/07/2024
  • 202229/06/2023
  • 202114/07/2022
  • 202016/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 52.00
0.00 (0.00%)
52.0053.0052.0010:0012:0014:0016:00
Open
PLN 53.50
High
PLN 53.50
Low
PLN 51.30
Volume
720
Avg. vol.
4.45K
Market cap
PLN 330.38M
P/E ratio
–
EPS
-PLN 6.97
Shares outstanding
6.35M
52-week
PLN 49.00 – 56.00
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 441.38kUSD -3.49mUSD -3.08m
Q1 2026USD 88.60kUSD -3.04mUSD -3.07m
Q4 2025USD 11.05kUSD -2.58mUSD -2.52m
Q3 2025USD 504.77kUSD -2.97mUSD -2.88m

Results for Q3 2026:Nov 19, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 13%
Top 8.4%
City · Wrocław1,995 / 13,650
Top 15%
Voivodeship · Dolnośląskie4,213 / 23,831
Top 18%
Country · Poland56,256 / 297,069
Top 19%

Results vs industry

Revenue
This companyUSD 2.29mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -10.57mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 14.56mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 10.00mMedianUSD 281.58kAverageUSD 8.35m

Offer

Websites

Job offers

The company has its own careers page: captortherapeutics.pl/kariera.

Authorized Representatives

Adam Łukojć age 42 – Management Board Member
Anna Pawluk age 45 – Management Board Member
Michał Jerzy Walczak age 41 – President of the Management Board

Manner of representation

If the management board is a one-person management board, the company is represented by one member of the management board. If the management board is a multi-member management board, the company is represented by two members of the management board acting jointly.

Supervisory board

Andrew Galazka – Supervisory Board Member
Charles Kunsch – Supervisory Board Member
Robert Florczykowski age 39 – Supervisory Board Member
Paweł Jerzy Holstinghausen-Holsten age 55 – Supervisory Board Member
Krzysztof Samotij age 74 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2016-01-01.

  • mBank
    44 1140 1140 0000 3452 9000 1002
  • mBank
    33 1140 1140 0000 3452 9000 1006
  • mBank
    87 1140 1140 0000 3452 9000 1004

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Dec 31, 2018Commercial Companies Code notice

Public aid

24 public aid cases recorded, with a total value of $66,481,965.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–
Aid for research and development projects: industrial research
–
Aid for research and development projects: experimental development
–

European Funds

ProjectEU co-financing
A first-in-class mcl-1 degrader to promote apoptosis in therapy-resistant liquid and solid tumours
$2.7M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
JJP Biologics sp. z o.o.
Lipid Systems sp. z o.o.
Biotechna S.A.
Molecure S.A.
Neuca Clinical Trials Investments sp. z o.o.
Scope Fluidics S.A.
Pikralida sp. z o.o.
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Vasa Therapeutics sp. z o.o.
Medicofarma Biotech S.A.

Change history

DateEvent
2026-10-19Share capital increase
2026-06-25Share capital increase
2025-04-29Share capital increase
2024-12-30Share capital increase
2024-12-12Share capital increase

FAQ

Last updated: 2026-10-19